Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment

Annals of Neurology

Volumn 43, Issue 3, 1998, Pages 311-317

  Schneider, J S ^a   Van Velson, M ^a   Menzaghi, F ^b   Lloyd, G K ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; LEVODOPA; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; MACACA; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TASK PERFORMANCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; COGNITION; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; LEVODOPA; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; NICOTINIC AGONISTS; PYRIDINES; PYRROLIDINES;

EID: 0031914621     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430308     Document Type: Article

References (38)

1. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270
2. Levin BE, Llabre MM, Weiner WJ. Cognitive impairments associated with early Parkinson's disease. Neurology 1989;39: 557-561
3. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115:1727-1751
4. Rogers D, Lees AJ, Smith E, et al. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness: an experimental study. Brain 1987;110:761-776
5. Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122
6. Flowers KA, Robertson C. The effect of Parkinson's disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry 1985;48:517-529
7. Dorros S. Parkinson's: A Patient's View. Washington, DC, Seven Locks Press, 1989
8. Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord 1992;7:110-116
9. Freedman M, Oscar-Berman M. Selective delayed response deficits in Parkinson's and Alzheimer's disease. Arch Neurol 1986; 43:886-890
10. Pillon B, Dubois B, Bonnet A-M, et al. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15 objects test. Neurology 1989;39:762-768
11. Sharpe MH. Distractibility in early Parkinson's disease. Cortex 1990;26:239-246
12. Sharpe MH. Auditory attention in early Parkinson's disease: an impairment in focused attention. Neuropsychologia 1992;30: 101-106
13. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988;111:299-321
14. Lange KW, Robbins TW, Marsden CD, et al. Levodopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992;107:394-404
15. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 1992;115:1701-1725
16. Sacaan AI, Reid RT, Santori EM, et al. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. J Pharmacol Exp Ther 1997;280:373-383
17. Menzaghi, F, Sacaan AI, Reid RT, et al. Characterization of SIB-1508Y, the active enantiomer of a novel nicotinic acetylcholine receptor (NAChR) agonist, SIB-1765F. Soc Neurosci Abstr 1996;22:1523
18. Pope-Coleman A, Lloyd GK, Schneider JS. The nicotinic receptor agonist SIB-1508Y potentiates L-dopa responses in parkinsonian monkeys. Soc Neurosci Abstr 1996;22:217
19. Van Velson M, Tinker J, Lloyd GK, et al. The nicotinic receptor agonist SIB-1508Y, but not levodopa, improves cognition in chronic MPTP-treated monkeys with and without motor disability. Soc Neurosci Abstr 1997;23:1898 (Abstract)
20. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 1995;123:55-63
21. Jones GMM, Sahakian BJ, Levy R, et al. Effects of nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992;108:485-494
22. Schneider JS, Roeltgen DP. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res 1993;615:351-354
23. Schneider JS, Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995;4:245-255
24. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 1982;298:199-209
25. Sharpe MH, Cermak SA, Say DS. Motor planning in Parkinson's disease. Neuropsychologia 1983;21:455-462
26. Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 1987;26:676-686
27. 1 ganglioside administration reverses cognitive deficits and delays onset of motor symptoms in a slowly progressing Parkinson model in monkeys. Soc Neurosci Abstr 1994;20:1646
28. 1 ganglioside treatment. Science 1992;256:843-846
29. Taylor JR, Elsworth JD, Roth RH, Sladek JR, Redmond DE. Cognitive and motor deficits in the acquisition of an object retrieval/detour reaching task in MPTP-treated monkeys. Brain 1990;113:617-637
30. Schneider JS, Kovelowski CJ. Chronic exposure to low doses of MPTP: I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 1990;519:122-128
31. Diamond A. Developmental time course in human infants and infant monkeys, and the neural basis of inhibitory control in reaching. Ann NY Acad Sci 1990;608:637-669
32. Schneider JS. Chronic exposure to low doses of MPTP: II. Neurochemical and pathological consequences in cognitively impaired, motor asymptomatic monkeys. Brain Res 1990;534: 25-36
33. Murphy BL, Arnsten AFT, Jentsch JD, Roth RH. Dopamine and spatial working memory in rats and monkeys: Pharmacological reversal of stress-induced impairment. J Neurosci 1996; 16:7768-7775
34. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. Brain 1986;109:845-883
35. Kulisevsky J, Avila A, Barbanoj M, et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-2132
36. Cosford ND, Bleicher L, Herbaut A, et al. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Medicinal Chem 1996;39: 3235-3237
37. Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-dopa in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther 1997;280:393-401
38. Menzaghi F, Whelan KT, Risbrough VB, et al. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther 1997;280:384-392